Whether you're building your first QMS, navigating a CDMO relationship, preparing for regulatory scrutiny, or exploring a licensing transaction — we'd like to hear about your challenge.
One of the most common questions from biotech founders and leadership teams is surprisingly simple: "Do we really need a Quality Management System at this stage?" The answer is rarely straightforward.
The real challenge is not deciding whether a company needs quality. The challenge is determining how much quality is needed, where controls should be implemented, and how those controls should evolve as the programme matures.
For an early-stage virtual biotech, quality should never become a bureaucratic exercise. Every procedure, review step, and governance structure consumes time, money, and management attention. At the same time, the absence of appropriate controls creates risks far more expensive than the systems designed to prevent them.
Outsourcing Operations ≠ Transferring Accountability. While many operational activities can be outsourced, accountability cannot. The sponsor remains responsible for the product entering clinical trials, regardless of how many external partners are involved. The sponsor's role is to maintain sufficient oversight — not to recreate the CDMO's QMS internally.
By the time a company approaches proof-of-concept, quality maturity often becomes a strategic consideration. Potential investors, licensing partners, and acquirers are evaluating whether the organisation understands its product, controls its supply chain, and can reliably execute development activities. Quality should be viewed as a business enabler, not a compliance burden. A well-designed QMS protects the value of the asset.
The objective is neither the smallest system nor the largest system. The objective is the right system — one that evolves alongside the product, protects patients, and enables execution.
Europe continues to produce world-class biotechnology innovation. China has spent the last decade building biological scale. Increasingly, competitive advantage is determined not by either capability alone, but by the ability to combine innovation, scale, and governance into a globally integrated development model.
China is no longer simply viewed as a manufacturing destination. It is increasingly becoming a biotechnology innovation and industrialization ecosystem, contributing not only manufacturing capacity but also development expertise, scientific talent, integrated platform capabilities, and growing innovation output.
The CDMO Shift. Only ten to fifteen years ago, many Western biotechnology companies viewed China primarily through the lens of cost reduction. During interactions with Chinese CDMOs, what stands out today is not cost, but the combination of speed, flexibility, technical capability, and determination to deliver results. Modern facilities have been built at a pace rarely seen elsewhere, staffed by a rapidly growing pool of highly educated scientists and quality professionals with practical experience across mAbs, bispecifics, ADCs, cell therapies, and other advanced modalities.
Biological scale is becoming as important as scientific innovation. Scientific innovation creates opportunity; biological scale enables its realization. Organizations that successfully combine both will be best positioned to accelerate development timelines, deploy capital efficiently, and deliver new therapies to patients.
Europe possesses world-class science but faces challenges in scaling biotechnology innovation, attracting late-stage investment, and expanding manufacturing capacity. The organizations that master the combination of European innovation and Chinese biological scale — within a robust quality governance framework — may define the next generation of biotechnology success.
For quality leaders and CDMO governance professionals, this creates both opportunity and complexity. Understanding how to build effective oversight models across geographies, regulatory frameworks, and operational cultures is where QULLA Partners brings particular value.
Connect on LinkedIn